Climb Bio (CLYM) vs Evotec (EVO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Climb Bio (CLYM) has outperformed Evotec (EVO) over the past year, gaining 549.1% versus a loss of 58.9%. Over five years, CLYM leads with a -33.6% price change compared with -92.9% for EVO. Climb Bio is the larger company by market cap ($606.0 million vs $554.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLYM | EVO |
|---|---|---|
| Share price | $10.55 | $1.56 |
| Market cap | $605.95M | $554.09M |
| 1-day change | -1.49% | -3.16% |
| YTD return | +167.75% | -47.73% |
| 1-year return | +549.09% | -58.93% |
| 5-year return | -33.64% | -92.87% |
| EPS (TTM) | $-0.82 | $-0.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.33 | $4.27 |
| 52-week low | $1.64 | $1.50 |
| Distance from 52-week high | -42.44% | -63.49% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +161.33% | +166.82% |
| Average volume | 1.38M | 103.98K |
| Shares outstanding | 57.44M | 355.39M |
| Employees | 28 | 4,461 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CLYM has outperformed EVO by 608.0 percentage points over the past year.
About Climb Bio
CLYM stock →Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
About Evotec
EVO stock →Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biologics.
Health Care · Biotechnology: Pharmaceutical Preparations · 4,461 employees
CLYM vs EVO FAQ
Which is bigger, Climb Bio or Evotec?
Climb Bio (CLYM) is larger, with a market capitalization of $605.95M compared with $554.09M for Evotec (EVO).
Which stock has performed better over the past year, CLYM or EVO?
CLYM returned +549.09% over the past 12 months, compared with -58.93% for EVO (price return, excluding dividends). Past performance does not predict future results.
Are Climb Bio and Evotec in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.